scholarly journals Malignant Lymph Node Neoplasm

2020 ◽  
Author(s):  
Keyword(s):  
Lymph Node ◽  
Malignant Lymph Node

Small lymphocytes: a morphometric study in the benign and malignant lymph node

1984 ◽  
Vol 17 (3) ◽  
pp. 217
Author(s):  
S.S. Silver ◽  
I. Dardick ◽  
B.F. Burns ◽  
D.R. Caldwell
Keyword(s):  
Lymph Node ◽  
Morphometric Study ◽  
Malignant Lymph Node

scholarly journals Follicular Lymphoma Tregs Have a Distinct Transcription Profile Impacting Their Migration and Retention in the Malignant Lymph Node

PLoS ONE ◽  
2016 ◽  
Vol 11 (5) ◽  
pp. e0155347 ◽  
Author(s):  
Hristina Nedelkovska ◽  
Alexander F. Rosenberg ◽  
Shannon P. Hilchey ◽  
Ollivier Hyrien ◽  
W. Richard Burack ◽  
...  
Keyword(s):  
Lymph Node ◽  
Follicular Lymphoma ◽  
Transcription Profile ◽  
Malignant Lymph Node

Parathyroid Adenoma Mimicking a Malignant Lymph Node on 18F-Choline PET-CT

2017 ◽  
Vol 42 (4) ◽  
pp. e207-e209 ◽  
Author(s):  
Bliede Van den Broeck ◽  
Daan De Maeseneer ◽  
Ruth De Gersem ◽  
Kathia De Man
Keyword(s):  
Lymph Node ◽  
Parathyroid Adenoma ◽  
Malignant Lymph Node ◽  
Choline Pet ◽  
Pet Ct

scholarly journals Monitoring Thyroglobulin in a Sensitive Immunoassay Has Comparable Sensitivity to Recombinant Human TSH-Stimulated Thyroglobulin in Follow-Up of Thyroid Cancer Patients

2007 ◽  
Vol 92 (1) ◽  
pp. 82-87 ◽  
Author(s):  
Robert C. Smallridge ◽  
Shon E. Meek ◽  
Melissa A. Morgan ◽  
Geoffrey S. Gates ◽  
Thomas P. Fox ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Lymph Node ◽  
Local Recurrence ◽  
Distant Metastasis ◽  
Residual Disease ◽  
Differentiated Thyroid Carcinoma ◽  
Detectable Level ◽  
Malignant Lymph Node ◽  
Recombinant Human Tsh

Abstract Context: Most thyroglobulin (Tg) assays have a sensitivity of 0.5–1 ng/ml. A minority of patients with undetectable T4-suppressed Tg levels have a recombinant human TSH (rhTSH)-stimulated Tg above 2 ng/ml and identifiable residual disease. Objective: The objective was to determine whether a Tg assay with improved sensitivity could eliminate the need for rhTSH stimulation when baseline Tg is below 0.1 ng/ml. Design: A retrospective study of two academic endocrine practices was conducted. Population: A total of 194 patients undergoing rhTSH stimulation participated in the study. Results: Of the 80 patients with Tg below 0.1 ng/ml, two (2.5%) had rhTSH-stimulated Tg above 2 ng/ml. One other patient with stimulation to 0.3 ng/ml and negative 123I scan had an ultrasound-detected malignant lymph node resected. None had 131I/123I imaging after rhTSH stimulation suggestive of local recurrence or distant metastasis. If T4-suppressed Tg was 0.1–0.5 or 0.6–2.0 ng/ml, rhTSH Tg was above 2 ng/ml in 24.2 and 82.4%, respectively. Conclusions: Patients with differentiated thyroid carcinoma and a T4-suppressed serum Tg below 0.1 ng/ml rarely have a rhTSH-stimulated Tg above 2 ng/ml, and none of these patients had 131I or 123I imaging after rhTSH stimulation suggestive of local recurrence or distant metastasis. We recommend monitoring such patients with a T4-suppressed Tg level and periodic neck ultrasonography. An increase in T4-suppressed serum Tg to a detectable level or the appearance of abnormal lymph nodes by physical or ultrasound exam should prompt further investigation.

Sign in / Sign up

Export Citation Format

Share Document